ARLINGTON, Mass.--(BUSINESS WIRE)--TetraGenetics Inc., an emerging biotechnology company engaged in the expression of ion channel drug targets, announced today another new partnership with one of the world’s “top ten” pharmaceutical companies. This will be TetraGenetics’ fifth program launched with either a large pharmaceutical and/or biotech partner for ion channel drug discovery.
The program utilizes TetraGenetics’ unique and proprietary ion channel production capabilities for the discovery of novel therapeutics targeting sodium channels for pain management. This particular program will begin immediately.
TetraGenetics’ CEO, Doug Kahn said “We chose to focus on ion channels several years ago due to their importance in therapeutic drug discovery and the limited availability of high quality material required to launch effective programs. This new partnership reinforces the value of TetraGenetics’ specific capabilities and materials.”
About TetraGenetics: TetraGenetics uses proprietary technology (TetraExpress™) to produce ion channel proteins in membrane preparations and in purified form for use in antibody discovery, structural biology and small molecule screening programs. The company uses these recombinant proteins to discover and develop new drugs for ion channel related autoimmune diseases and pain management. For more information, please visit: www.tetragenetics.com